Press Release
Babraham’s 5th Biotechnology Investment Forum draws French Biotech Companies
9th May 2008
Babraham Bioscience Technologies (BBT) held its fifth Biotechnology Investment Forum (BIF) at the Babraham Research Campus on 1st May. Ten new companies were profiled, seeking investment ranging from £500k to £3M. For the first time at this Forum, two French companies, CellVir and NOKAD from a Bioincubator near Paris, took the opportunity to pitch their technology and business to potential investors. Bioventures based in Edinburgh, Sheffield, Norwich, and Liverpool, were also selected.
Approximately 60 delegates attended the Forum, which aims to encourage bioscience investment through presentation and networking opportunities for investors and bioscience companies. A diverse array of technologies was showcased including: novel vaccine technologies; new generations of anti-retroviral compounds; screening systems for hospital acquired infections and strategies to combat antibiotic resistance; implantable nano-materials targeting the orthopaedic markets and a system to predict tumour responsiveness to chemotherapy, thereby enabling a more individualised and effective treatment strategy.
The Guest Lectures were given by Ray Coole, Chairman of Matrix Private Funds Group, discussing the current institutional investment in early stage technologies and Tim Fell, COO of CellCentric, presenting the company’s novel approach to maximising innovation potential in the field of epigenetics and regenerative medicine.
The Forum was established in February 2006 to provide new and early-stage biomedical companies seeking funding with an opportunity to pitch their propositions to a forum of Venture Capital and Business Angel investor groups with special interest in biotechnology. Since their inception, 74 companies have presented at the Babraham Investment Forum meetings.
Plans for the 6th event are already underway, which is expected to be held in early October 2008. Companies and potential investors who would like to attend the next meeting are encouraged to contact Babraham Bioscience Technologies direct.
Derek Jones, Chief Business Officer of BBT commented, “We were delighted to have attracted two companies from Genopole in France. Through these events BBT has played a pivotal role in stimulating partnerships between entrepreneurs and investors and we hope that this will stimulate interaction with other Bioventures from across Europe at our 6th Investment Forum in October.”
Latest Press Releases
- Epigenetic regulation of a genetic gatekeeper, Elf5, provides new insights into cell fate decisions during early development
- Evolutionary origin of mammalian gene regulation unravelled 150 million years by Anglo-Australian-American consortium
- Babraham scientists highlighted for contribution to UK economy
- New Investment In Babraham To Spark Life-Saving Drug Discovery, UK
- Babraham’s 5th Biotechnology Investment Forum draws French Biotech Companies
- Traditional Chinese Medicine Company announced as the 50th Company to join the Babraham Bioincubator at the official opening of 'Meditrina'
- Biotechnology Investment Forum bridges the bioclusters in Babraham and Boston, USA
- New Bioincubation Facilities on the Babraham Research Campus set to open in September 2007
- Babraham Institute wins regional award for work with schools
- Minuscule molecules pack a powerful punch in immune defence
Spread your message to an audience that counts, with options available for our website, email bulletins and publications including The House Magazine.
